Merck CEO Ken Frazier says the first vaccines against Covid-19, should they meet the 50 percent efficacy threshold set by the U.S. Food and Drug Administration, may not have as broad of an impact as hoped.
Drugmakers partnered with the U.S. government are on track to begin actively manufacturing a vaccine for COVID-19 by the end of the summer, a senior administration official said.
Ovid Therapeutics and Angelini Pharma entered into an exclusive license agreement to develop, manufacture and commercialize OV101 for the treatment of Angelman syndrome in Europe.
Emergent BioSolutions entered a five-year manufacturing services deal with Janssen Pharmaceutical to manufacture Johnson & Johnson’s Ad26.COV2-S COVID-19 vaccine.
Amidst the pandemic, the biopharma industry continues to surge ahead as BioSpace reviews companies that have made recent job announcement expansions.
With Moderna on the precipice of launching a Phase III trial of 30,000 people for the COVID-19 vaccine mRNA-1273, the company is ramping up manufacturing capabilities and is partnering with Catalent.
AstraZeneca signed a tenth supply-and-manufacturing deal for the company’s experimental COVID-19 vaccine with a Scotland-backed firm as the British drugmaker ramps up efforts for wider trials of the potential treatment.
Johnson & Johnson intends to start human trials of a potential COVID-19 vaccine in the second half of July, two months earlier than planned.
Glass maker Corning will receive $204 million from the U.S. government to boost the manufacturing capacity of vials that will be used to store coronavirus vaccines and treatments.
The U.S. government entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine.
